**Study Overview:** This study is testing a new treatment, PTX-022, which is a gel that contains 3.9% sirolimus. It is being tested to see if it's safe and works well for treating angiokeratomas. Angiokeratomas are small, dark skin spots caused by blood vessels that are close to the skin's surface. **Who Can Join?** - **Age:** You must be at least 6 years old. - **Condition:** You need to have been diagnosed with angiokeratoma. - **Commitment:** You must agree to follow all study rules and procedures. **Who Cannot Join?** - **Health Conditions:** If you have a serious health condition that might interfere with the study. - **Allergies:** If you are allergic to sirolimus or similar medications. - **Compliance:** If you are unable to stick to the study's rules and procedures. **Key Points:** - **Study Duration:** There will be multiple visits during the study. - **Compensation:** Participants may receive compensation for their time and travel. - **Risks:** There might be side effects from the gel, especially if allergic. This is a baseline-controlled study, meaning your own initial condition will serve as a comparison to see how well the treatment works.